Achilles Therapeutics plc
ACHL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $16 | $14 | $10 | $16 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | -$1 | -$1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20 | $18 | $13 | $19 |
| Operating Income | -$20 | -$18 | -$14 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $2 | $1 |
| Pre-Tax Income | -$20 | -$16 | -$12 | -$18 |
| Tax Expense | -$0 | $0 | -$0 | $1 |
| Net Income | -$20 | -$16 | -$12 | -$19 |
| % Margin | – | – | – | – |
| EPS | -0.48 | -0.41 | -0.3 | -0.47 |
| % Growth | -17.1% | -36.7% | 36.2% | – |
| EPS Diluted | -0.48 | -0.41 | -0.3 | -0.47 |
| Weighted Avg Shares Out | 40 | 40 | 40 | 40 |
| Weighted Avg Shares Out Dil | 40 | 40 | 40 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$20 | -$17 | -$13 | -$18 |
| % Margin | – | – | – | – |